Hyperbaric Oxygen and Radiotherapy
The potential importance of the so-called "oxygen effect" in radiotherapy was recognized by the late L. H. Gray and his colleagues in 1953.1 Many experimental studies have supported this view.2 If a cell is deprived of oxygen, its sensitivity to damage by x rays is reduced nearly three times, but it is not materially increased in the presence of excess oxygen. There is increasing evidence that many, if not all, of the larger malignant tumours in man contain some anoxic cells due to abnormal blood supply and that these cells may survive the largest x-ray dose it is possible to give in clinical practice. Thus they lead to regrowth of the tumour. It is in an effort to overcome this oxygen effect that many patients with advanced growths are given hyperbaric oxygen to breathe for a period immediately before and during radiotherapy.
Though 17 years have elapsed since I. Churchill-Davidson and his colleagues3 first reported encouraging results from the use of hyperbaric oxygen as an adjunct to radiotherapy, its exact value is still a subject for debate. Early workers in the field have been blamed for this in that they did not institute properly controlled trials from the beginning. This criticism, however, is hardly realistic, for treatment with hyperbaric oxygen and radiotherapy used to take between three and four hours to give and required that the patient be given a general anaesthetic to prevent oxygen convulsions. It was therefore impossible to follow the then conventional radiotherapeutic practice of splitting the total x-ray dose into daily fractions over a period of four to six weeks. A completely new dose-fractionation scheme involving a much smaller number of treatments more widely spaced had to be devised. Initially, though the local tumour clearance rate was high, the radionecrosis rate proved unacceptable, and it took several years to find a suitable technique. During this time many workers4-8 became so convinced of the value of hyperbaric oxygen in the treatment of advanced tumours, particularly in the head and neck and the uterine cervix, that ethical difficulties prevented them from undertaking any controlled trial. A feature particularly noted was the greatly enhanced response to treatment of secondary squamous carcinoma in lymph nodes notably resistant to conventional radiotherapy. H. A. S. Van den Brenk did in fact start randomized trials in advanced cancer of the head and neck and bladder in 1965, but they were soon discontinued when it was agreed that the hyperbaric groups fared considerably better than the air-treated controls. A recent independent retrospective survey9 of cases treated by van In general the picture is hopeful that this form of treatment is an advance, and hyperbaric oxygen chambers have become a feature of many radiotherapy departments throughout the world. It seems likely that their use will become mandatory in the treatment of large growths at certain sites, especially squamous carcinomata with metastases to lymph nodes. There is less indication for using oxygen as an adjunct to radiotherapy in small tumours. Attempts are also now being made to develop particle irradiation-for example, with neutrons and 7r mesons whose cell-killing effect is less dependent on the presence of oxygen than is the case with x rays.
